William Blair Starts LogicBio Therapeutics (LOGC) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- Kroger cuts same-store sales outlook, keeps earnings guidance
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Chardan Capital Markets Starts LogicBio Therapeutics (LOGC) at Buy
November 13, 2018 6:47 AM ESTChardan Capital Markets analyst Gbola Amusa initiates coverage on LogicBio Therapeutics (NASDAQ: LOGC) with a Buy rating and a price target of $20.00.
The analyst comments "LogicBios pipeline reflects a focus on indications that play to its strengths. The advantage lies in indications where 1)... More
Barclays Starts LogicBio Therapeutics (LOGC) at Overweight
November 13, 2018 4:16 AM ESTBarclays analyst Gena Wang initiates coverage on LogicBio Therapeutics (NASDAQ: LOGC) with a Overweight rating and a price target of $24.00.
For an analyst ratings summary and ratings history on LogicBio Therapeutics click here. For more ratings news on LogicBio Therapeutics click here.
Shares of LogicBio Therapeutics closed at $13.72 yesterday.
... More